Friday, August 7, 2026

AI Experts Call for Stronger Deepfake Regulation to Combat Misinformation

As generative AI technology-abused Deepfakes are ramping up on various social media platforms...

If The US President Were Gore Instead Of Bush… Would The North Korean Nuclear Issue Have Been Different?[Inter-Korean Relations Back Then]

The article discusses the Sunshine Policy, U.S.-North Korea relations, and the impact of political changes on the nuclear crisis.

DELIBERATE Blinders: US State Department DITCHES Urgent Threat of Kim-Putin Axis To Focus On Abstract ‘Supply Chains’

Secretary Rubio met with South Korea and Japan's foreign ministers at APEC, focusing on trilateral cooperation and North Korea's denuclearization.

Tag: GC Biopharma

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Exclusive: GC Biopharma Seeks First Phase 2 Trial for Homegrown mRNA Vaccine This Week

GC Biopharma advances to Phase 2 of South Korea's mRNA vaccine program, aiming for late-stage trials after Phase 1 completion.

GC Biopharma Unveils mRNA Vaccine Strategy at Seoul Pandemic X Summit 2026: What’s Next for COVID-19?

GC Biopharma presents its mRNA vaccine strategy at the Seoul Pandemic X Summit 2026, focusing on rapid responses to future pandemics.

GC Biopharma Presents Aggregation Study of Alyglo IVIG… A New Benchmark for Safe Immunotherapy

GC Biopharma USA will present findings on IVIG formulations, highlighting Alyglo's lower protein aggregation and improved stability at NHIA 2026.

GC Biopharma Targets Full Utilization of Plasma Centers with FDA Approval of ABO Plasma

GC Biopharma's ABO Plasma gains FDA approval for its Laredo center, enhancing plasma sourcing and operational efficiency ahead of schedule.

GC Biopharma’s Varicella Vaccine “VARICELLAJU” Wins Approval in Guatemala

GC Biopharma's varicella vaccine VARICELLAJU gains marketing approval in Guatemala, marking its Latin American debut and ensuring safety.

GC Biopharma Corp Soars After Eight Years on the Back of Immunodeficiency Drug Alyglo, Posting Results in U.S. Market Push

GC Biopharma Corp breaks its fourth-quarter deficit with ALYGLO's success, achieving $106M in annual revenue and plans for future growth.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.